Aging Populations And China Expansion Will Drive Device Adoption

Published
11 Mar 25
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
US$64.70
18.0% undervalued intrinsic discount
08 Aug
US$53.06
Loading
1Y
16.4%
7D
12.0%

Author's Valuation

US$64.7

18.0% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on08 Aug 25

Despite consensus revenue growth forecasts increasing to 6.4% and future P/E declining to 26.83x, LivaNova’s analyst price target remained unchanged at $64.70. What's in the News LivaNova raised full-year 2025 revenue growth guidance to 8.0-9.0% (constant currency) and 9.0-10.0% (organic).

Shared on01 May 25
Fair value Increased 8.38%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 2.44%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 0.92%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 0.24%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.